Outcome of Secondary Glaucoma in Eyes With Uveal Melanoma A Population-Based Analysis.

Authors

Anni E Stadigh, Päivi M Puska, Tero T Kivelä

Published in

Journal of glaucoma. Oct 08, 2026. Epub Oct 08, 2026.

Abstract

Over 50% of eyes with uveal melanoma and secondary glaucoma with ≥20/400 vision retain that level through 5 years, and over 90% with <20/400 vision are pain-free. Over 90% avoid secondary enucleation for intractable glaucoma.
To report outcome of secondary glaucoma in uveal melanoma eyes mainly treated with brachytherapy.
Of 186 consecutive patients with uveal melanoma and secondary glaucoma, 49 (26%) with ≥20/400 vision were assigned to therapeutic and 137 (74%) with <20/400 vision to palliative group. Glaucoma-related medications and procedures were recorded. Main outcome measures were best corrected visual acuity, pain, and enucleation.
The therapeutic group had thinner (median, 7.5 vs. 9.1 mm), more anterior tumors (median distance to disc and foveola, 10 vs. 3.5 mm and 12 vs. 3.6 mm, respectively; 29% vs. 11% iris melanomas) than the palliative group. The main mechanism of secondary glaucoma was angle invasion (45%) and neovascularization (71%), respectively. In the therapeutic group, 96% and 47% of eyes were managed with medication and cyclophotocoagulation, respectively, compared to 77% and 20% in the palliative one. At 1, 3, and 5 years, 60%, 69%, and 67% in the therapeutic group were normotensive (4-21 mmHg), 63%, 55%, and 58% preserved ≥20/400 vision, and 28%, 36%, and 46% also retained ≥20/60 vision, respectively. Low vision at patient level (3%, 4%, and 5%, respectively) was exceptional. In the palliative group, 84%, 92%, and 96% were free of pain, respectively, and cumulative incidence of enucleation for secondary glaucoma was 9% by 5 years.
Most uveal melanoma eyes with secondary glaucoma and useful vision potential become normotensive with medication and cyclophotocoagulation and retain ≥20/400 vision. Most with less visual potential become pain-free without intensive medication and avoid enucleation.

PMID:
42852930
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.